Urinary interleukin-1β levels among gynecological patients

Journal of Ovarian Research

Patricia A Kruk¹  Ambuj Kumar²  Santo V Nicosia³  Joshua Kraft⁴  Mitchel S Hoffman⁴  Kamisha T Woolery³ 

[1] H. Lee Moffitt Cancer Center, Tampa 33612, FL, USA;Department of Internal Medicine, University of South Florida, Tampa 33612, FL, USA;Department of Pathology and Cell Biology, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa 33612, FL, USA;Department of Obstetrics and Gynecology, University of South Florida, Tampa 33612, FL, USA

关键词: Body mass index;    Urine;    Ovarian cancer;    Obesity;    Interleukin-1 beta;   

Others  :  1151661
DOI  :  10.1186/s13048-014-0104-4

 received in 2014-06-26, accepted in 2014-10-26,  发布年份 2014

【 摘 要 】

Background

Early detection of epithelial ovarian cancer (OC) is necessary to overcome the high mortality rate of late stage diagnosis; and, examining the molecular changes that occur at early disease onset may provide new strategies for OC detection. Since the deregulation of inflammatory mediators can contribute to OC development, the purpose of this pilot study was to determine whether elevated urinary levels of Interleukin-1beta (IL-1 beta) are associated with OC and associated clinical parameters.

Methods

Urinary and serum levels of IL-1 beta were analyzed by ELISA from a patient cohort consisting of healthy women (N?=?10), women with ovarian benign disease (N?=?23), women with OC (N?=?32), women with other benign gynecological conditions (N?=?22), and women with other gynecological cancers (N?=?6).

Results

Average urinary IL-1 beta levels tended to be elevated in ovarian benign (1.26 pg/ml) and OC (1.57 pg/ml) patient samples compared to healthy individuals (0.36 pg/ml). Among patients with benign disease, urinary IL-1? levels were statistically higher in patients with benign inflammatory gynecologic disease compared to patients with non-inflammatory benign disease. Interestingly, urinary IL-1 beta levels tended to be 3-6x greater in patients with benign ovarian disease or OC as well as with a concomitant family history of ovarian and/or breast cancer compared to similar patients without a family history of ovarian and/or breast cancer. Lastly, there was a pattern of increased urinary IL-1 beta with increasing body mass index (BMI); patients with a normal BMI averaged urinary IL-1 beta levels of 0.92 pg/ml, overweight BMI averaged urinary IL-1 beta levels of 1.72 pg/ml, and obese BMI averaged urinary IL-1 beta levels of 5.26 pg/ml.

Conclusions

This pilot study revealed that urinary levels of IL-1 beta are elevated in patients with epithelial OC supporting the thought that inflammation might be associated with cancer progression. Consequently, further studies of urinary IL-1 beta and the identification of an inflammatory profile specific to OC development may be beneficial to reduce the mortality associated with this disease.

【 授权许可】

   
2014 Woolery et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]American Cancer Society: Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
• [2]Nguyen L, Cardenas-Goicoechea SJ, Gordon P, Curtin C, Momeni M, Chuang L, Fishman D: Biomarkers for early detection of ovarian cancer. Womens Health (Lond Engl) 2013, 9(2):171-185. quiz 186¿177
• [3]Cragun JM: Screening for ovarian cancer. Cancer Control 2011, 18(1):16-21.
• [4]PROLOG Gynecology and Surgery. 6th edition. American College of Obstetricians and Gynecologists, Washington, D.C; 2009.
• [5]Markowska J, Manys G, Kubaszewska M: Value of CA 125 as a marker of ovarian cancer. Eur J Gynaecol Oncol 1992, 13(4):360-365.
• [6]Carlson KJ, Skates SJ, Singer DE: Screening for ovarian cancer. Ann Intern Med 1994, 121(2):124-132.
• [7]Su Z, Graybill WS, Zhu Y: Detection and monitoring of ovarian cancer. Clin Chim Acta 2013, 415:341-345.
• [8]Lewis AM, Varghese S, Xu H, Alexander HR: Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006, 4:48.
• [9]Mustea A, Pirvulescu C, Konsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J: Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 2008, 42(1):77-84.
• [10]Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organ Tech Rep Ser 2000, 894:1-253. i-xii
• [11]Dinarello CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
• [12]Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454(7203):436-444.
• [13]Kisielewski R, Tolwinska A, Mazurek A, Laudanski P: Inflammation and ovarian cancer¿current views. Ginekol Pol 2013, 84(4):293-297.
• [14]Female age-related fertility decline. Committee Opinion No. 589 Fertil Steril 2014, 101(3):633-634.
• [15]Gerard N, Caillaud M, Martoriati A, Goudet G, Lalmanach AC: The interleukin-1 system and female reproduction. J Endocrinol 2004, 180(2):203-212.
• [16]Caillaud M, Duchamp G, Gerard N: In vivo effect of interleukin-1beta and interleukin-1RA on oocyte cytoplasmic maturation, ovulation, and early embryonic development in the mare. Reprod Biol Endocrinol 2005, 3:26.
• [17]Vural P, Akgul C, Canbaz M: Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res 2006, 54(4):298-302.
• [18]Dinarello CA: The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 2006, 25(3):307-313.
• [19]Burney RO, Giudice LC: Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012, 98(3):511-519.
• [20]Vassiliadis S, Relakis K, Papageorgiou A, Athanassakis I: Endometriosis and infertility: a multi-cytokine imbalance versus ovulation, fertilization and early embryo development. Clin Dev Immunol 2005, 12(2):125-129.
• [21]Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ: Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur Cytokine Netw 2013, 24(3):106-113.
• [22]Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, Okuda H, Kudo T: Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999, 82(1):107-110.
• [23]Hefler-Frischmuth K, Hefler LA, Heinze G, Paseka V, Grimm C, Tempfer CB: Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol 2009, 147(1):65-68.
• [24]Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, Curry E, Gabra H, Stronach E, El-Bahrawy M: Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine 2013, 64(1):413-421.
• [25]Lim D, Oliva E: Precursors and pathogenesis of ovarian carcinoma. Pathology 2013, 45(3):229-242.
• [26]Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies PLoS Med 2012, 9(4):e1001200.
• [27]Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Goodman MT, Carney ME, Matsuno R, Lurie G, Moysich K, Kjaer A, Hogdall E, Goode E, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, et al.: Obesity and risk of ovarian cancer subtypes: evidence from the ovarian cancer association consortium. Endocr Relat Cancer 2013, 20(2):251-262.
• [28]Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, Schatzkin A, Lacey JV Jr: Body mass index and risk of ovarian cancer. Cancer 2009, 115(4):812-822.
• [29]Canchola AJ, Chang ET, Bernstein L, Largent JA, Reynolds P, Deapen D, Henderson KD, Ursin G, Horn-Ross PL: Body size and the risk of ovarian cancer by hormone therapy use in the California teachers study cohort. Cancer Causes Control 2010, 21(12):2241-2248.
• [30]Delort L, Kwiatkowski F, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ: Central adiposity as a major risk factor of ovarian cancer. Anticancer Res 2009, 29(12):5229-5234.
• [31]Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami HO, Arslan A, Beeson WL, van den Brandt PA, Buring JE, Folsom AR, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Lacey JV Jr, Leitzmann M, Lukanova A, Marshall JR, Miller AB, Patel AV, Rodriguez C, Rohan TE, Ross JA, Wolk A, Zhang SM, Smith-Warner SA: Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 2008, 17(4):902-912.
• [32]Kotsopoulos J, Baer HJ, Tworoger SS: Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses¿ health study. Obesity (Silver Spring) 2010, 18(8):1625-1631.
• [33]Brandstedt J, Nodin B, Manjer J, Jirstrom K: Anthropometric factors and ovarian cancer risk in the Malmo diet and cancer study. Cancer Epidemiol 2011, 35(5):432-437.
• [34]McGee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung N, Kim-Sing C, Karlan B, Foulkes WD, Ainsworth P, Ghadirian P, Senter L, Eisen A, Sun P, Narod SA: Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers. Obesity (Silver Spring) 2012, 20(6):1288-1292.
• [35]Engeland A, Tretli S, Bjorge T: Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 2003, 95(16):1244-1248.
• [36]Maccio A, Madeddu C: Inflammation and ovarian cancer. Cytokine 2012, 58(2):133-147.
• [37]Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, McLaughlin JR, Sun P, Narod SA: Height, weight, BMI and ovarian cancer survival. Gynecol Oncol 2012, 127(1):83-87.
• [38]Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, Lavasani S, Walsh BW, Anderson G, Vitolins M, Sarto G, Irwin ML: Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women¿s health initiative. Gynecol Oncol 2014, 133(1):4-10.
• [39]Bae HS, Kim HJ, Hong JH, Lee JK, Lee NW, Song JY: Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis. J Ovarian Res 2014, 7:41.
• [40]Au-Yeung G, Webb PM, DeFazio A, Fereday S, Bressel M, Mileshkin L: Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 2014, 133(1):16-22.
• [41]Field KM, Kosmider S, Jefford M, Michael M, Jennens R, Green M, Gibbs P: Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008, 4(3):108-113.
• [42]Thanos D, Maniatis T: The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992, 71(5):777-789.
• [43]Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schafer R, Tchernitsa O: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008, 123(2):348-356.
• [44]Califano D, Pignata S, Losito NS, Ottaiano A, Greggi S, De Simone V, Cecere S, Aiello C, Esposito F, Fusco A, Chiappetta G: High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. J Cell Physiol 2014, 229(1):53-59.
• [45]Warburg O: On the origin of cancer cells. Science 1956, 123(3191):309-314.
• [46]Fabian C, Koetz L, Favaro E, Indraccolo S, Mueller-Klieser W, Sattler UG: Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS J 2012, 279(5):882-891.
• [47]Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, Baba T, Hamanishi J, Abiko K, Kosaka K, Murphy SK, Mori S, Konishi I: Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.Mol Carcinog 2013. doi:10.1002/mc.22072.
• [48]Makowski L, Zhou C, Zhong Y, Kuan PF, Fan C, Sampey BP, Difurio M, Bae-Jump VL: Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer. Gynecol Oncol 2014, 133(1):90-97.
• [49]McGettrick AF, O¿Neill LA: NLRP3 and IL-1beta in macrophages as critical regulators of metabolic diseases. Diabetes Obes Metab 2013, 15(Suppl 3):19-25.
• [50]Donath MY, Dalmas E, Sauter NS, Boni-Schnetzler M: Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab 2013, 17(6):860-872.
• [51]Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
• [52]Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52(3):812-817.
• [53]Chae JS, Paik JK, Kang R, Kim M, Choi Y, Lee SH, Lee JH: Mild weight loss reduces inflammatory cytokines, leukocyte count, and oxidative stress in overweight and moderately obese participants treated for 3 years with dietary modification. Nutr Res 2013, 33(3):195-203.
• [54]Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, Dayer JM, Reinecke M, Halban PA, Donath MY: Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 2004, 101(21):8138-8143.
• [55]Diaz ES, Karlan BY, Li AJ: Obesity-associated adipokines correlate with survival in epithelial ovarian cancer. Gynecol Oncol 2013, 129(2):353-357.
• [56]Hong MY, Tseng CC, Chuang CC, Chen CL, Lin SH, Lin CF: Urinary macrophage migration inhibitory factor serves as a potential biomarker for acute kidney injury in patients with acute pyelonephritis. Mediators Inflamm 2012, 2012:381358.
• [57]Pruijm M, Ponte B, Vollenweider P, Mooser V, Paccaud F, Waeber G, Marques-Vidal P, Burnier M, Bochud M: Not all inflammatory markers are linked to kidney function: results from a population-based study. Am J Nephrol 2012, 35(3):288-294.
• [58]Pereira AB, Teixeira AL, Rezende NA, Pereira RM, Miranda DM, Oliveira EA, Teixeira MM, Simoes ESAC: Urinary chemokines and anti-inflammatory molecules in renal transplanted patients as potential biomarkers of graft function: a prospective study. Int Urol Nephrol 2012, 44(5):1539-1548.
• [59]Basso B, Gimenez F, Lopez C: IL-1beta, IL-6 and IL-8 levels in gyneco-obstetric infections. Infect Dis Obstet Gynecol 2005, 13(4):207-211.
• [60]Corwin EJ, Bozoky I, Pugh LC, Johnston N: Interleukin-1beta elevation during the postpartum period. Ann Behav Med 2003, 25(1):41-47.
• [61]Corwin EJ, Johnston N, Pugh L: Symptoms of postpartum depression associated with elevated levels of interleukin-1 beta during the first month postpartum. Biol Res Nurs 2008, 10(2):128-133.
• [62]Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zhabina AS, Gorodnova TV, Komarov YI, Bogdanov AA, Sokolenko AP, Imyanitov EN: Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol 2014, 31:199.
• [63]Hjerpe E, Brage SE, Frostvik SM, Johansson H, Shoshan M, Avall-Lundqvist E: Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites. Int J Gynecol Cancer 2014, 24(8):1389-1394.
• [64]Gabrielson M, Bjorklund M, Carlson J, Shoshan M: Expression of mitochondrial regulators PGC1? and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinoma. PloS One 2014, 9(9):e107109.
• [65]Bogush TA, Didko EA, Semakov AV, Bogush EA, Tjulandina AS, Zarkua VT, Tjulandina SA, Davydov MI: Immunofluorescent assay of ERCC1 and estimation of clincial significance of the protein expression in ovarian cancer tissue. Biochem Biophys Mol Biol 2014, 457:1410-1445.
• [66]Jakimovska M, Cerne K, Verdenik I, Kobal B: Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites. Radiol Oncol 2014, 48(3):307-313.
• [67]Bourgeois MM, Richards IS: Gender-specific differences in the urinary expression of aldosterone, IL-1alpha and IL-1beta. Biomark Med 2010, 4(6):843-847.